Tom graduated from Durham University in 2017 with an MChem degree in Chemistry. He spent the final year of his degree within the Epigenetics department at GSK in Stevenage working on the "Synthesis and bioactivity of BET bromodomain inhibitors." Following his degree, Tom worked for two years as a Research Scientist for AMRI based at the Eli Lilly Erl Wood site. He provided synthetic organic chemistry support for a wide variety of Eli Lilly and Elanco projects.
Tom joined the Brennan Group in July 2019 to work as part of the Alzheimer's Research UK Oxford Drug Discovery Institute.